Evan David Seigerman
Stock Analyst at BMO Capital
(2.81)
# 1,856
Out of 4,734 analysts
31
Total ratings
23.33%
Success rate
6.45%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Maintains: Outperform | $156 → $105 | $81.03 | +29.58% | 5 | Dec 23, 2024 | |
| MRK Merck & Co. | Downgrades: Market Perform | $136 → $105 | $96.24 | +9.10% | 3 | Dec 20, 2024 | |
| REPL Replimune Group | Maintains: Outperform | $14 → $18 | $11.85 | +51.90% | 2 | Nov 22, 2024 | |
| ABBV AbbVie | Maintains: Outperform | $228 → $208 | $172.61 | +20.50% | 5 | Nov 12, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,300 → $1,190 | $687.80 | +73.02% | 5 | Nov 1, 2024 | |
| GPCR Structure Therapeutics | Maintains: Outperform | $83 → $100 | $28.34 | +252.86% | 2 | Jun 7, 2024 | |
| AMGN Amgen | Maintains: Outperform | $336 → $355 | $274.81 | +29.18% | 3 | May 3, 2024 | |
| PFE Pfizer | Reiterates: Outperform | $33 → $36 | $26.64 | +35.14% | 4 | May 2, 2024 | |
| CADL Candel Therapeutics | Maintains: Outperform | $9 → $3 | $6.61 | -54.58% | 1 | May 15, 2023 | |
| LLY Eli Lilly | Maintains: Outperform | $369 → $396 | $742.35 | -46.66% | 1 | Sep 6, 2022 |
Novo Nordisk
Dec 23, 2024
Maintains: Outperform
Price Target: $156 → $105
Current: $81.03
Upside: +29.58%
Merck & Co.
Dec 20, 2024
Downgrades: Market Perform
Price Target: $136 → $105
Current: $96.24
Upside: +9.10%
Replimune Group
Nov 22, 2024
Maintains: Outperform
Price Target: $14 → $18
Current: $11.85
Upside: +51.90%
AbbVie
Nov 12, 2024
Maintains: Outperform
Price Target: $228 → $208
Current: $172.61
Upside: +20.50%
Regeneron Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $1,300 → $1,190
Current: $687.80
Upside: +73.02%
Structure Therapeutics
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $28.34
Upside: +252.86%
Amgen
May 3, 2024
Maintains: Outperform
Price Target: $336 → $355
Current: $274.81
Upside: +29.18%
Pfizer
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $26.64
Upside: +35.14%
Candel Therapeutics
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $6.61
Upside: -54.58%
Eli Lilly
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $742.35
Upside: -46.66%